Skip to Content

Brain and Spine Tumors Clinical Trials

A randomized, Double-blind, Phase II Trial of Surgery, Radiation Theray Plus Temozolomide and Pembroliumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Aims: The purpose of this study is to find out if adding immunotherapy (pembrolizumab) with or without a vaccine (HSPPC-96) to standard of care treatment for GBM improves survival of newly diagnosed GBM subjects. The standard treatment for GBM consists of surgery to remove the brain tumor, radiation and chemotherapy (temozolomide).
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH18-383
Contact: Call 847.570.2025 with questions regarding the study
Open to Enrollment: Yes

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Aims:
The purpose of this Phase III study is to finally attain a clear answer to the long-standing question of which treatment route leads to the best clinical outcome for patients with newly diagnosed WHO grade II meningioma. Subjects will be randomly assigned into one of two groups: Group 1 will be observed following surgery and Group 2 will receive radiation therapy following surgery.
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH18-270
Contact: Call 847.570.2025 with questions regarding the study
Open to Enrollment: Yes

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab versus Temozolomide in Patients with Newly Diagnosed Mgmt (Tumor O-6-Methylguanine Dna Methyltransferase) Unmethylated Glioblastoma
Aim: The purpose of the study is to find out whether adding ipilimumab and nivolumab to radiotherapy will significantly prolong progression free survival versus adding temozolomide to radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation.
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH20-366
Contact: Call 847.570.2025 with questions regarding the study
Open to Enrollment: Yes

A PHASE II STUDY OF CHECKPOINT BLOCKADE IMMUNOTHERAPY IN PATIENTS WITH SOMATICALLY HYPERMUTATED RECURRENT GLIOBLASTOMA    

Aim: Glioblastoma multiforme (GBM) is the most aggressive of the primary brain tumors. It remains uniformly lethal, and there are no treatments that extend survival once it recurs. The purpose of this study is to determine whether the combination of ipilimumab and nivolumab can lower the chance of recurrent glioblastoma with elevated mutational burden from growing or spreading after initial therapy failed. For this study, “high mutational burden” is defined as at least 20 mutations on the Foundation One CDx test.
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH21-065
Contact: Call 847.570.2025 with questions regarding the study
Open to Enrollment: Yes

PHASE II TRIAL of the IMMUNE CHECKPOINT INHIBITOR NIVOLUMAB in PATIENTS with SELECT RARE CNS CANCERS 

Aim: There are more than 130 identified primary tumors of Central Nervous System(CNS) and because these tumors are so rare there are insufficient proven therapies. Most of these neoplasms are surgically resected followed by treatment with radiotherapy. With few exceptions, there are no effective systemic regimens and even in chemotherapy sensitive disease, most patients with recurrence eventually have no remaining salvage treatments available. The purpose of this study is to determine whether nivolumab can shrink tumors that have returned in patients with rare CNS (brain or spine) tumors or increase the time it takes for these tumors to grow or spread throughout the body.
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number:
EH21-004
Contact:
Call 847.570.2025 with questions regarding the study
Open to Enrollment:
Yes